Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03417544 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
A Phase 2 study of HER2-positive Metastatic Breast Cancer and Central Nervous System Metastases, sponsored by Nancy Lin, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT03417544: Active Phase 2 study of HER2-positive Metastatic Breast Cancer and Central Nervous System Metastases, sponsored by Nancy Lin, MD.
NCT03417544 is a Phase 2 study of HER2-positive Metastatic Breast Cancer and Central Nervous System Metastases that is active but no longer recruiting, run by Nancy Lin, MD. The registered enrollment target is 19 participants, below the 122-participant average among 11 other HER2-positive Metastatic Breast Cancer trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03417544, a Phase 2 study of HER2-positive Metastatic Breast Cancer and Central Nervous System Metastases, is active but no longer recruiting, sponsored by Nancy Lin, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain. The names of the study drugs involved in this study are: * Atezolizumab * Pertuzumab * Trastuzumab
Primary Outcome
The proportion of patients who had confirmed complete response or confirmed partial response, assessed using neuro-oncology-brain metastases (RANO-BM) criteria. RANO-BM assess the response of brain metastases to treatment, using MRI scan. There are four categories as results: Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD), which is separately defined as disappearance of all target lesions, at least a 30% decrease in the sum of the diameters of ta
Conditions Studied
Interventions
- DRUG ATEZOLIZUMAB
- DRUG PERTUZUMAB
- DRUG TRASTUZUMAB
Study Locations (2)
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What the registry record for NCT03417544 still lists
NCT03417544 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 122-participant average among 11 other HER2-positive Metastatic Breast Cancer trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with HER2-positive Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which ATEZOLIZUMAB is the first listed.
NCT03417544 reports a single indexed study location in Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03417544 about?
NCT03417544 is a clinical study titled "Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC". This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain. The names of the study drugs involved in this study are: * Atezolizumab * Pertuzumab * Trastuzumab
What is the current status of trial NCT03417544?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-05-21. Estimated completion is 2025-12.
What conditions does trial NCT03417544 study?
This clinical trial studies the following conditions: HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases.
What interventions are being tested in trial NCT03417544?
The interventions under investigation include: ATEZOLIZUMAB (DRUG), PERTUZUMAB (DRUG), TRASTUZUMAB (DRUG).
Who is sponsoring clinical trial NCT03417544?
This trial is sponsored by Nancy Lin, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03417544 being conducted?
This trial has 2 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03417544's enrollment target sits among peer trials
19 12th of 11 the lowest of 11 other HER2-positive Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-positive Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
ACTIVE NOT RECRUITING · Phase 2
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
RECRUITING · NA
-
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
RECRUITING
-
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI